Press Releases

Eagle Pharmaceuticals, Inc., announced it has reached agreement on the terms of a transfer of the entire issued and to be issued share capital of Acacia Pharma Group plc (“Acacia Pharma”) (EURONEXT: ACPH) to Eagle by way of a scheme of arrangement under Part 26 of the United Kingdom’s Companies Act 2006 (the “Scheme”). The terms of the proposed transaction value Acacia Pharma’s existing issued and to be issued share capital at approximately €

The American Pharmacists Association’s (APhA’s) House of Delegates (HOD) passed policy in order to break down barriers that stand in the way of patients’ ability to receive optimal and accessible care through pharmacists. Now is the time for all health care professions to work together to expand access to care during this critical moment for our nation. There are no other health care professionals with more extensive training in medication use and safety than pharm

MaaT Pharma , a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer, announced today that the first patient has been dosed in its pivotal Phase 3 trial investigating MaaT013 in patients with acute Graft-versus-Host-Disease with gastrointestinal involvement (GI-aGvHD) who are refractory to both steroids, the standard of care first-line treatment, and to ruxolitinib1 used as a se

CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited , today announced the definitive notice of the end result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd.  for USD 179.25 per share as indicated in the offer prospectus of 18 January 2022.   According to the definitive end result, taking into account the Vifor Pharma shares held by the offeror and the persons acting in concert

CANbridge Pharmaceuticals, Inc. a China-based global biopharmaceutical company committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, announced that the first patient has been dosed in the CAN106 Phase 1b/2 trial for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in China. The multi-center, open-label, Phase 1b/2 study to evaluate the tolerability, efficacy, safety and PK/PD of CAN106 administered intravenousl

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Amryt Pharma Plc (NASDAQ: AMYT), SelectQuote, Inc. (NYSE: SLQT), Porch Group, Inc. (NASDAQ: PRCH), and Virgin Galactic Holdings, Inc. (NYSE: SPCE). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

Bristol Myers Squibb today announced that the U.S. Food and Drug Administration  has extended the review of the supplemental biologics license application (sBLA) for Reblozyl® (luspatercept-aamt) for the treatment of anemia in adults with non-transfusion-dependent (NTD) beta thalassemia to June 27, 2022. Reblozyl is being developed and commercialized through a global collaboration with Merck & Co., Inc., known as MSD outside the United States and Canada, following Merck’s a

MEI Pharma, Inc.  and Kyowa Kirin Co., Ltd.  today provided an update after a recent meeting with the U.S. Food Drug Administration (FDA) to discuss the pursuit of a marketing authorization for zandelisib, a phosphatidylinositol-3-kinase (“PI3K”) inhibitor drug candidate, via the accelerated approval pathway under 21 CFR Part 314.500, Subpart H, based on data generated by the single arm Phase 2 TIDAL study. In the meeting, the FDA informed the companies of its position t

ABIONYX Pharma, a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, announced today the publication in Biomedecines of the first clinical data demonstrating that CER-001 limits inflammation effects in acute inflammatory conditions such as COVID-19. COVID-19 is associated with respiratory symptoms characterized by acute lung injury, rapidly progressing to acute respiratory distress syndrome. The pulmonary dysfunction is ra

RespireRx Pharmaceuticals Inc., a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, in association with Jeffrey King Managing Attorney at Patent Networks Law Group, is pleased to announce that it has filed a provisional patent application describing novel lipid based formulation technology (LFT) that may be used to improve the solubility and bioavailability of poorly soluble drugs, particularly can